Erasca, Inc. (ERAS) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Erasca reported revenue of $0. Net income was -$124.5M, or -$0.44 per diluted share. Operating activities generated -$95.5M of cash, leaving -$95.6M of free cash flow. At fiscal year end, Erasca held $396.2M in total assets against $71.0M in total liabilities, including $73.8M of cash and equivalents.
Open the full interactive Erasca financials → Quarterly statements, key ratios, valuation history and price charts.
Erasca Key Stats
| Share Price | $14.78 |
|---|---|
| Market Cap | $4.60B |
| 52-Week Range | $2.20 – $22.47 |
| Shares Outstanding | 311.3 million (basic, 2026 Q2) |
Erasca Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$124.9M | -$247.4M | -$141.5M | -$179.6M | -$140.9M |
| Pre-Tax Income | -$122.8M | -$242.8M | -$125.0M | -$161.7M | -$124.5M |
| Income Tax | — | — | — | — | $0 |
| Net Income | -$122.8M | -$242.8M | -$125.0M | -$161.7M | -$124.5M |
| Diluted EPS | -$1.85 | -$1.99 | -$0.83 | -$0.69 | -$0.44 |
Erasca Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$30.6M | -$29.1M | -$183.4M | -$44.1M |
| Diluted EPS | -$0.11 | -$0.10 | -$0.60 | -$0.14 |
Erasca Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $360.5M | $284.2M | $93.1M | $67.7M | $73.8M |
| Current Assets | $420.0M | $444.5M | $320.7M | $308.8M | $286.2M |
| Total Assets | $501.4M | $514.9M | $395.3M | $502.5M | $396.2M |
| Current Liabilities | $26.4M | $48.7M | $26.2M | $31.4M | $28.5M |
| Total Liabilities | $44.9M | $103.1M | $78.6M | $79.0M | $71.0M |
| Shareholders' Equity | $456.5M | $411.9M | $316.7M | $423.5M | $325.2M |
Erasca Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | -$79.6M | -$103.3M | -$101.2M | -$109.4M | -$95.5M |
| Cash From Investing | -$64.6M | -$71.1M | -$91.2M | -$156.6M | $100.4M |
| Cash From Financing | $439.4M | $98.1M | $1.3M | $240.7M | $1.1M |
| Free Cash Flow | -$90.8M | -$117.8M | -$103.0M | -$109.5M | -$95.6M |
Figures from Erasca's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Erasca financials page for every line item.
Erasca Company Profile
| Ticker | ERAS |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | San Diego, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001761918 |
Frequently Asked Questions
What was Erasca's revenue in fiscal 2025?
Erasca (ERAS) reported revenue of $0 for fiscal 2025.
What is Erasca's annual revenue history?
Erasca's annual revenue by fiscal year: 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Erasca's net income in fiscal 2025?
Erasca reported net income of -$124.5M for fiscal 2025.
What was Erasca's earnings per share (EPS) in fiscal 2025?
Erasca's diluted EPS was -$0.44 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Erasca generate in fiscal 2025?
Erasca generated -$95.6M of free cash flow in fiscal 2025.
What was Erasca's revenue last quarter?
In its most recent reported quarter (2026 Q2), Erasca reported revenue of $0.
How many shares of Erasca are outstanding?
Erasca reported a weighted average of 311.3 million basic shares outstanding in 2026 Q2.
What is Erasca's market cap?
Based on its latest closing price, Erasca (ERAS) has a market capitalization of about $4.60B.
When does Erasca's fiscal year end?
Erasca's fiscal year end, as registered with the SEC, is December 31.
Where is Erasca headquartered?
Erasca lists its business address in San Diego, California in its SEC filings.